Home/Pipeline/AT-527

AT-527

COVID-19

Phase 2Partnered (Roche)

Key Facts

Indication

COVID-19

Phase

Phase 2

Status

Partnered (Roche)

Company

Atea Pharmaceuticals

About Atea Pharmaceuticals

Atea Pharmaceuticals is a Boston-based biotech focused on discovering and developing oral antiviral therapies for RNA viruses, leveraging a proprietary platform of purine nucleos(t)ide prodrugs. Its lead asset, a combination of bemnifosbuvir (polymerase inhibitor) and ruzasvir (NS5A inhibitor), is in Phase 3 development for hepatitis C with topline data expected in 2026. Founded by antiviral veteran Jean-Pierre Sommadossi, the company's strategy targets significant unmet needs in HCV and other RNA viral diseases with convenient oral regimens designed for high efficacy and a high barrier to resistance.

View full company profile

Therapeutic Areas

Hepatitis C Hepatitis E Viral Infections

Other COVID-19 Drugs

Drug	Company	Phase	Status
COVID-19 Severity Prediction Test	Age Labs	Development	Active
PanCytoVir™ (oral probenecid)	TrippBio	Phase 2	Active
OT-101	Sapu BioScience	Clinical Trial (Phase not specified)	Active
Idylla SARS-CoV-2 Test	Biocartis	Approved	CE-IVD
COVID-19 Vaccine Testing (for AstraZeneca)	Advaxia Biologics	Approved	Active
COVID-19 Vaccine Clinical Batches	Advaxia Biologics	Clinical	Active
UOL COVID-19 Test	Uh-Oh Labs	Approved	Active
Lagevrio (molnupiravir)	Ridgeback Biotherapeutics	Approved/EUA	Active
CVXGA	CyanVac	Phase 2	Active
SARS-CoV-2 Test	NanoPin Technologies	Commercial (LDT)	Active
Emeramide for COVID-19	EmeraMed	Preclinical	Active
COVID-19 Oral Therapeutic (with Sen-Jam Pharmaceutical)	KVK Tech	Development	Active